Ionis Pharmaceuticals
IONS
392 hedge funds and large institutions have $9.53B invested in Ionis Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 94 funds opening new positions, 107 increasing their positions, 127 reducing their positions, and 29 closing their positions.
224% more first-time investments, than exits
New positions opened: 94 | Existing positions closed: 29
50% more capital invested
Capital invested by funds: $6.36B → $9.53B (+$3.16B)
19% more funds holding
Funds holding: 329 → 392 (+63)
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
0.72% less ownership
Funds ownership: 85.59% → 84.87% (-0.72%)
16% less repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 127
51% less call options, than puts
Call options by funds: $109M | Put options by funds: $223M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$85M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.6M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$25.9M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$23.9M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$21.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
-$65.6M |
| 2 |
ClearBridge Investments
New York
|
-$56.9M |
| 3 |
Goldman Sachs
New York
|
-$44.8M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$39.2M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$19.6M |
IONS Hedge Fund Activity: Q1 2019 in Review
392 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q1 2019, worth a combined $9.53B — up 50% from $6.36B a quarter earlier.
Buyers outnumbered sellers: 94 funds opened new IONS positions and 29 closed out — a net gain of 65 holders — while 107 added to existing stakes and 127 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $85M. The largest seller was BB Biotech, cutting an estimated $65.6M.
- 392 institutional investors held Ionis Pharmaceuticals (IONS) as of Q1 2019, up from 329 in Q4 2018.
- Funds reported $9.53B of Ionis Pharmaceuticals stock for Q1 2019, up 50% quarter-over-quarter.
- 94 funds opened new Ionis Pharmaceuticals positions in Q1 2019 and 29 closed out, a net change of +65 holders.
- The largest Ionis Pharmaceuticals buyer in Q1 2019 was T. Rowe Price Associates, an estimated $85M added.
- The largest Ionis Pharmaceuticals seller in Q1 2019 was BB Biotech, an estimated $65.6M sold.
Based on aggregated 13F filings for Q1 2019.